Ezetimibe and its inhibitory effects on intestinal cholesterol absorption

Helen H. Wang, Frank Lammert, David Q.H. Wang

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Because intestinal cholesterol absorption is a major determinant of serum low-density lipoprotein (LDL) cholesterol concentrations, understanding the genetic regulation of cholesterol absorption may lead to novel approaches to the treatment of cardiovascular diseases that affect millions of people in Westernised societies. Recent research suggests that ATP-binding cassette (ABC) transporters ABCG5 and ABCG8 represent an apical sterol export pump that may promote active efflux of cholesterol and plant sterols from enterocytes back into the intestinal lumen for excretion. The newly identified Niemann-Pick C1 like 1 (NPC1L1) protein is also expressed at the apical surface of enterocytes and plays a critical role in the ezetimibe-sensitive cholesterol absorption pathway. These findings strongly support the notion that cholesterol absorption is a multistep process that is regulated by multiple genes at the enterocyte level. The efficiency of cholesterol absorption could be determined by the net effect between influx and efflux of intraluminal cholesterol molecules across the brush border of the enterocyte. Ezetimibe is a novel, specific and potent cholesterol absorption inhibitor that effectively blocks intestinal absorption of dietary and biliary cholesterol. It decreases serum LDL cholesterol levels up to 20%. Such effects are needed in the therapy of difficult-to treat lipid disorders, including the rare homozygous familial hypercholesterolemia and sitosterolemia. The efficacy, safety, and tolerability of both ezetimibe monotherapy and coadministration therapy with a statin have been evaluated in clinical trials. Combination therapy using cholesterol absorption (NPC1L1) inhibitor (ezetimibe) and HMG-CoA reductase inhibitors (statins) offers an efficacious new strategy for the prevention and treatment of hypercholesterolemia.

Original languageEnglish (US)
Pages (from-to)165-175
Number of pages11
JournalVascular Disease Prevention
Volume2
Issue number2
DOIs
StatePublished - Apr 1 2005
Externally publishedYes

Fingerprint

Intestinal Absorption
Cholesterol
Enterocytes
Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
Anticholesteremic Agents
Dietary Cholesterol
Phytosterols
Hyperlipoproteinemia Type II
ATP-Binding Cassette Transporters
Ezetimibe
Sterols
Microvilli
Hypercholesterolemia
Serum
Cardiovascular Diseases
Therapeutics
Clinical Trials
Lipids
Safety

Keywords

  • Bile acid
  • Cholesterol transporter
  • Chylomicron
  • Lymph
  • Micelle
  • Nutrition
  • Plant sterol
  • Statin

ASJC Scopus subject areas

  • Epidemiology
  • Cardiology and Cardiovascular Medicine

Cite this

Ezetimibe and its inhibitory effects on intestinal cholesterol absorption. / Wang, Helen H.; Lammert, Frank; Wang, David Q.H.

In: Vascular Disease Prevention, Vol. 2, No. 2, 01.04.2005, p. 165-175.

Research output: Contribution to journalReview article

@article{595d460186094e7fb7d79c7ae75f456d,
title = "Ezetimibe and its inhibitory effects on intestinal cholesterol absorption",
abstract = "Because intestinal cholesterol absorption is a major determinant of serum low-density lipoprotein (LDL) cholesterol concentrations, understanding the genetic regulation of cholesterol absorption may lead to novel approaches to the treatment of cardiovascular diseases that affect millions of people in Westernised societies. Recent research suggests that ATP-binding cassette (ABC) transporters ABCG5 and ABCG8 represent an apical sterol export pump that may promote active efflux of cholesterol and plant sterols from enterocytes back into the intestinal lumen for excretion. The newly identified Niemann-Pick C1 like 1 (NPC1L1) protein is also expressed at the apical surface of enterocytes and plays a critical role in the ezetimibe-sensitive cholesterol absorption pathway. These findings strongly support the notion that cholesterol absorption is a multistep process that is regulated by multiple genes at the enterocyte level. The efficiency of cholesterol absorption could be determined by the net effect between influx and efflux of intraluminal cholesterol molecules across the brush border of the enterocyte. Ezetimibe is a novel, specific and potent cholesterol absorption inhibitor that effectively blocks intestinal absorption of dietary and biliary cholesterol. It decreases serum LDL cholesterol levels up to 20{\%}. Such effects are needed in the therapy of difficult-to treat lipid disorders, including the rare homozygous familial hypercholesterolemia and sitosterolemia. The efficacy, safety, and tolerability of both ezetimibe monotherapy and coadministration therapy with a statin have been evaluated in clinical trials. Combination therapy using cholesterol absorption (NPC1L1) inhibitor (ezetimibe) and HMG-CoA reductase inhibitors (statins) offers an efficacious new strategy for the prevention and treatment of hypercholesterolemia.",
keywords = "Bile acid, Cholesterol transporter, Chylomicron, Lymph, Micelle, Nutrition, Plant sterol, Statin",
author = "Wang, {Helen H.} and Frank Lammert and Wang, {David Q.H.}",
year = "2005",
month = "4",
day = "1",
doi = "10.2174/1567270053507219",
language = "English (US)",
volume = "2",
pages = "165--175",
journal = "Vascular Disease Prevention",
issn = "1567-2700",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Ezetimibe and its inhibitory effects on intestinal cholesterol absorption

AU - Wang, Helen H.

AU - Lammert, Frank

AU - Wang, David Q.H.

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Because intestinal cholesterol absorption is a major determinant of serum low-density lipoprotein (LDL) cholesterol concentrations, understanding the genetic regulation of cholesterol absorption may lead to novel approaches to the treatment of cardiovascular diseases that affect millions of people in Westernised societies. Recent research suggests that ATP-binding cassette (ABC) transporters ABCG5 and ABCG8 represent an apical sterol export pump that may promote active efflux of cholesterol and plant sterols from enterocytes back into the intestinal lumen for excretion. The newly identified Niemann-Pick C1 like 1 (NPC1L1) protein is also expressed at the apical surface of enterocytes and plays a critical role in the ezetimibe-sensitive cholesterol absorption pathway. These findings strongly support the notion that cholesterol absorption is a multistep process that is regulated by multiple genes at the enterocyte level. The efficiency of cholesterol absorption could be determined by the net effect between influx and efflux of intraluminal cholesterol molecules across the brush border of the enterocyte. Ezetimibe is a novel, specific and potent cholesterol absorption inhibitor that effectively blocks intestinal absorption of dietary and biliary cholesterol. It decreases serum LDL cholesterol levels up to 20%. Such effects are needed in the therapy of difficult-to treat lipid disorders, including the rare homozygous familial hypercholesterolemia and sitosterolemia. The efficacy, safety, and tolerability of both ezetimibe monotherapy and coadministration therapy with a statin have been evaluated in clinical trials. Combination therapy using cholesterol absorption (NPC1L1) inhibitor (ezetimibe) and HMG-CoA reductase inhibitors (statins) offers an efficacious new strategy for the prevention and treatment of hypercholesterolemia.

AB - Because intestinal cholesterol absorption is a major determinant of serum low-density lipoprotein (LDL) cholesterol concentrations, understanding the genetic regulation of cholesterol absorption may lead to novel approaches to the treatment of cardiovascular diseases that affect millions of people in Westernised societies. Recent research suggests that ATP-binding cassette (ABC) transporters ABCG5 and ABCG8 represent an apical sterol export pump that may promote active efflux of cholesterol and plant sterols from enterocytes back into the intestinal lumen for excretion. The newly identified Niemann-Pick C1 like 1 (NPC1L1) protein is also expressed at the apical surface of enterocytes and plays a critical role in the ezetimibe-sensitive cholesterol absorption pathway. These findings strongly support the notion that cholesterol absorption is a multistep process that is regulated by multiple genes at the enterocyte level. The efficiency of cholesterol absorption could be determined by the net effect between influx and efflux of intraluminal cholesterol molecules across the brush border of the enterocyte. Ezetimibe is a novel, specific and potent cholesterol absorption inhibitor that effectively blocks intestinal absorption of dietary and biliary cholesterol. It decreases serum LDL cholesterol levels up to 20%. Such effects are needed in the therapy of difficult-to treat lipid disorders, including the rare homozygous familial hypercholesterolemia and sitosterolemia. The efficacy, safety, and tolerability of both ezetimibe monotherapy and coadministration therapy with a statin have been evaluated in clinical trials. Combination therapy using cholesterol absorption (NPC1L1) inhibitor (ezetimibe) and HMG-CoA reductase inhibitors (statins) offers an efficacious new strategy for the prevention and treatment of hypercholesterolemia.

KW - Bile acid

KW - Cholesterol transporter

KW - Chylomicron

KW - Lymph

KW - Micelle

KW - Nutrition

KW - Plant sterol

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=16444374056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16444374056&partnerID=8YFLogxK

U2 - 10.2174/1567270053507219

DO - 10.2174/1567270053507219

M3 - Review article

AN - SCOPUS:16444374056

VL - 2

SP - 165

EP - 175

JO - Vascular Disease Prevention

JF - Vascular Disease Prevention

SN - 1567-2700

IS - 2

ER -